ATE336491T1 - Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung - Google Patents

Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Info

Publication number
ATE336491T1
ATE336491T1 AT03757108T AT03757108T ATE336491T1 AT E336491 T1 ATE336491 T1 AT E336491T1 AT 03757108 T AT03757108 T AT 03757108T AT 03757108 T AT03757108 T AT 03757108T AT E336491 T1 ATE336491 T1 AT E336491T1
Authority
AT
Austria
Prior art keywords
production
therapeutic use
piperazinylacylpiperidine
derivatives
piperazinylacylpiperidine derivatives
Prior art date
Application number
AT03757108T
Other languages
English (en)
Inventor
Francoise Bono
Michael Bosch
Santos Victor Dos
Jean Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE336491T1 publication Critical patent/ATE336491T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT03757108T 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung ATE336491T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07

Publications (1)

Publication Number Publication Date
ATE336491T1 true ATE336491T1 (de) 2006-09-15

Family

ID=29724874

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03757109T ATE325122T1 (de) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
AT03757108T ATE336491T1 (de) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03757109T ATE325122T1 (de) 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Country Status (29)

Country Link
US (2) US7468368B2 (de)
EP (2) EP1513836B1 (de)
JP (2) JP4441401B2 (de)
KR (1) KR100970812B1 (de)
CN (1) CN100448875C (de)
AR (2) AR040246A1 (de)
AT (2) ATE325122T1 (de)
AU (2) AU2003255645A1 (de)
BR (1) BR0311828A (de)
CA (1) CA2487840C (de)
CY (2) CY1107330T1 (de)
DE (2) DE60305037T2 (de)
DK (2) DK1513835T3 (de)
EA (1) EA007501B1 (de)
ES (2) ES2264001T3 (de)
HR (1) HRP20041157B1 (de)
IS (1) IS2302B (de)
MA (1) MA27233A1 (de)
ME (1) MEP11508A (de)
MX (1) MXPA04012341A (de)
NO (1) NO329669B1 (de)
NZ (1) NZ537044A (de)
PL (1) PL208711B1 (de)
PT (2) PT1513835E (de)
RS (2) RS52588B (de)
TW (2) TWI283671B (de)
UA (1) UA77526C2 (de)
WO (2) WO2003104225A1 (de)
ZA (1) ZA200409823B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
KR20070036148A (ko) * 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 신경병성 질환의 치료에 적합한 피페리딘, 피페라진 혹은모르폴린의 이량체 화합물 또는 그들의 ７-원 유사체
EP2289510A1 (de) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten
EP1871420A4 (de) * 2005-04-15 2010-09-22 Univ North Carolina Verfahren zur ermöglichung des überlebens von zellen über neurotrophin-mimetika
EP2137179B1 (de) * 2007-03-15 2015-09-02 Merck Sharp & Dohme Corp. Als glucansynthaseinhibitoren geeignete pyridazinonderivate
EP2162135A4 (de) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc Zusammensetzungen, synthese und verfahren zur anwendung von atypischen antipsychotika auf chinolinon-basis
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US9062015B2 (en) 2009-12-14 2015-06-23 Merck Patent Gmbh Inhibitors of sphingosine kinase
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (de) 2011-12-20 2013-06-26 Sanofi Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
CN112911935A (zh) 2018-09-18 2021-06-04 金翅雀生物公司 哒嗪酮及其使用方法
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
EP3858439A1 (de) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amidderivate mit multimodaler aktivität gegen schmerzen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994455A (en) * 1987-10-26 1991-02-19 Pfizer Inc. Anti-anxiety agents
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
ATE325122T1 (de) 2006-06-15
RS20050014A (sr) 2007-06-04
EP1513836B1 (de) 2006-05-03
KR20050008802A (ko) 2005-01-21
MEP11508A (en) 2010-06-10
MA27233A1 (fr) 2005-02-01
AR040246A1 (es) 2005-03-23
JP2005534661A (ja) 2005-11-17
JP4441401B2 (ja) 2010-03-31
CY1107330T1 (el) 2012-11-21
EA007501B1 (ru) 2006-10-27
KR100970812B1 (ko) 2010-07-16
IS7579A (is) 2004-12-02
CN1675203A (zh) 2005-09-28
HK1076110A1 (zh) 2006-01-06
HRP20041157B1 (en) 2012-11-30
EP1513835B1 (de) 2006-08-16
CA2487840C (en) 2011-05-17
AR040247A1 (es) 2005-03-23
CY1105784T1 (el) 2011-02-02
DE60305037D1 (de) 2006-06-08
HRP20041157A2 (en) 2005-06-30
DE60307632T2 (de) 2007-08-09
AU2003255644B2 (en) 2009-02-05
AU2003255644A1 (en) 2003-12-22
PT1513835E (pt) 2006-12-29
CA2487840A1 (en) 2003-12-18
JP2005533051A (ja) 2005-11-04
US20050176722A1 (en) 2005-08-11
TW200400185A (en) 2004-01-01
NZ537044A (en) 2006-08-31
ES2271637T3 (es) 2007-04-16
UA77526C2 (en) 2006-12-15
EP1513835A1 (de) 2005-03-16
TWI319400B (en) 2010-01-11
AU2003255645A1 (en) 2003-12-22
JP4437075B2 (ja) 2010-03-24
EP1513836A1 (de) 2005-03-16
IS2302B (is) 2007-10-15
ES2264001T3 (es) 2006-12-16
ZA200409823B (en) 2006-07-26
WO2003104226A1 (fr) 2003-12-18
NO20045331L (no) 2005-03-07
RS52588B (sr) 2013-04-30
WO2003104225A1 (fr) 2003-12-18
PT1513836E (pt) 2006-09-29
NO329669B1 (no) 2010-11-29
TWI283671B (en) 2007-07-11
US7294628B2 (en) 2007-11-13
TW200407321A (en) 2004-05-16
DK1513835T3 (da) 2006-12-27
PL208711B1 (pl) 2011-05-31
PL374729A1 (en) 2005-10-31
BR0311828A (pt) 2005-03-29
CN100448875C (zh) 2009-01-07
EA200401470A1 (ru) 2005-06-30
DE60305037T2 (de) 2006-12-14
MXPA04012341A (es) 2005-09-30
US7468368B2 (en) 2008-12-23
US20060167007A1 (en) 2006-07-27
DE60307632D1 (de) 2006-09-28
DK1513836T3 (da) 2006-09-11

Similar Documents

Publication Publication Date Title
ATE441635T1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
ATE336491T1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE310003T1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE409184T1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE412635T1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
DE60336907D1 (de) Spirobifluorenderivate, deren herstellung und deren verwendung
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE469131T1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE316966T1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
IS7829A (is) Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE423119T1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE69905714D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische anwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE60304596D1 (de) In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1513835

Country of ref document: EP